Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
ADNOC Gas Targets Up to $4B Profit in 2026 
West Lafayette, Ind., Feb. 22, 2018 -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Feb. 26th, at 8:30 a.m. EST to discuss its fourth quarter and full year financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
The webcast will be recorded and available on the Company’s website for 90 days following the call.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering Phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR-T therapy into the clinic in 2018, where it will be studied in pediatric osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
